Connect with us

coronavirus

COVID-19: Latest on evaluation and authorization of vaccines

SHARE:

Published

5 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

MEPs will quiz EMA Executive Director Emer Cooke on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.

Today (23 March), European Medicines Agency (EMA) Executive Director Emer Cooke will update Members of the Environment, Public Health and Food Safety (ENVI) Committee on the status of approving COVID-19 vaccines. They will also discuss the EMA’s recent evaluation of the AstraZeneca vaccine.

When: Tuesday 23 March 2021, 10.00-11.00 (indicative timing)

Where: European Parliament in Brussels, room Paul-Henri Spaak (3C050) and videoconference

You can watch the debate live here.

Background

Following positive scientific recommendations, the EMA has authorized four vaccines against COVID-19 for use in the EU (BioNTech-Pfizer, Moderna, AstraZeneca and Johnson & Johnson). Two additional contracts have been concluded that will allow vaccines to be purchased once they have proven to be safe and effective: Sanofi-GSK and CureVac (both under rolling review). Exploratory talks were also concluded with two companies, Novavax and Valneva. The EMA also started a rolling review of the Sputnik V vaccine (which is not part of the EU’s COVID-19 vaccines portfolio).

Advertisement

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC), responsible for evaluating safety issues for human medicines, investigated whether the COVID-19 AstraZeneca vaccine can cause thromboembolic events. The results were presented on 18 March 2021, concluding that the benefits of the vaccine still outweigh the risks, despite a possible link to rare blood clots.

More information 

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending